Clinical Effect of Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes Mellitus Combined with HFpEF
Objective:To investigate the clinical efficacy and safety of Metformin Hydrochloride and Empagliflozin Tablets in the treatment of type 2 diabetes mellitus(T2DM)patients with ejection fraction preserving heart failure(HFpEF).Method:Eighty patients with T2DM complicated with HFpEF in Baoding NO.1 Central Hospital from October 2021 to September 2022 were selected and divided into observation group(n=40)and control group(n=40)by random number table method.The control group was treated with conventional drugs,and the observation group was treated with Metformin Hydrochloride and Empagliflozin Tablets on the basis of the control group's medication.Both groups received continuous treatment for 6 months.Blood glucose index,cardiac function index and adverse reactions were compared between the two groups.Result:After treatment,fasting blood glucose(FBG),2 h postprandial blood glucose(2 h PG)and glycated hemoglobin(HbA1c)in both groups were lower than those before treatment,and those of observation group were lower than those of control group(P＜0.05).After treatment,the left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)and brain natriuretic peptide(BNP)in both groups were better than those before treatment,the observation group were better than those of control group(P＜0.05).The incidence of adverse reactions in observation group(5.0%)was lower than that in control group(22.5%),the difference was statistically significant(P＜0.05).Conclusion:Metformin Hydrochloride and Empagliflozin Tablets has a significant clinical effect in the treatment of type 2 diabetes mellitus combined with HFpEF,which can reduce the blood glucose level of patients and improve the related indicators of cardiac function,and has high safety.
HFpEFMetformin Hydrochloride and Empagliflozin TabletsBlood glucoseHeart function
万方数据
维普
